ClinicalTrials.gg
CompletedNCT06178718Updated Apr 25, 2025Results posted

A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules

A Phase 1 interventional study of TNP-2092 capsules and TNP-2092 placebo capsules in Hyperammonemia, sponsored by TenNor Therapeutics (Suzhou) Limited. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by TenNor Therapeutics (Suzhou) Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 years 6 months after the study started (first participant enrolled Jun 2016, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The aim of the study was to evaluate the tolerability and pharmacokinetic characteristics of TNP-2092 Capsules after single-dose administration in healthy subjects, and the food effect on pharmacokinetics.

Read the detailed description

This was a single-center, randomized, double-blind, placebo-controlled, dose-ascending single-dose-administration study, and a study on the food effects on pharmacokinetics. Five dose groups of 100 mg, 200 mg, 400 mg, 800 mg, and 1200 mg will be set up.

The 100 mg, 200 mg, 800 mg, and 1200 mg groups will complete the single ascending dose study, with 10 subjects randomized in each group, 8 subjects receiving TNP-2092 and 2 receiving placebo. The drug will be administered once in each group in the fasting state, and tolerability will be evaluated on D4. Subjects were sequentially enrolled into different dose groups in ascending order of dose, and only when the previous lower dose was confirmed to be safe and well tolerated could they be enrolled into the next higher dose group.

The 400 mg group will complete the single ascending dose study, food effect study and undergo the metabolic transformation evaluation. A total of 18 subjects will be enrolled in the group and randomized into Group A and Group B, with 8 subjects receiving the investigational product and 1 receiving placebo. The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days. In terms of the administration sequence, Group A will first take TNP-2092 Capsules or placebo in the fasting state, and then TNP-2092 Capsules or placebo in the fed state; Group B will first take TNP-2092 Capsules or placebo in the fed state, and then TNP-2092 Capsules or placebo in the fasting state. Tolerability evaluation will be conducted on D4 and at the end of the study of food effects on pharmacokinetics (D8).

02

Conditions studied

  • Hyperammonemia

Browse trials for

03

In context

Hyperammonemia

25 studies on the registry are indexed under Hyperammonemia; 3 are open to participants now.

This study's enrollment of 58 is above the median of 31 across 16 interventional studies indexed under Hyperammonemia.

Browse Hyperammonemia studies →

Lead sponsor

TenNor Therapeutics (Suzhou) Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sex: male or female;
  • Age: 18-45 years, inclusive;
  • : 19.0-26.0 kg/m2, inclusive;
  • Female subjects of must agree to practice abstinence or take effective measures during the study and at least 70 days (10 weeks) after administration;
  • Male subjects must agree to practice abstinence or use condoms as a contraceptive measure during the study and at least 70 days (10 weeks) after administration;
  • Subjects whose clinical laboratory test results are within the normal range or whose test results are abnormal, but judged by the investigator to be of no clinical insignificance;
  • Those who do not smoke, or have smoked less than 5 cigarettes per day within 3 months before screening; those who do not drink alcohol, or have drunk less than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine) within 6 months before screening; those who have not smoked or drunk alcohol within 48 hours before admission to the study site;
  • Those who are fully informed of and understand this study, and have signed the Form;
  • Those who are willing to follow and able to complete all the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Those with symptoms or medical history of cardiovascular, digestive, respiratory, urinary, neurological, blood, immune, endocrine system diseases or tumor, mental illness, or any situation which, in the opinion of the investigator, may threaten the safety of the subjects or affect the correctness of the study results;
  • Pregnant or lactating women;
  • Those whose blood pressure above 150/90 mmHg or below 85/55 mmHg (supine position);
  • Those with regular use of any prescription/over-the-counter drugs, including vitamins, minerals, nutritional supplements or herbs, within 2 weeks before enrollment and during the study;
  • Those who are positive, syphilis positive, surface antigen positive, antibody positive, and/or with a positive drug urine test result;
  • Those who have a history of alcohol or drug abuse in the past 10 years; Those with an allergic constitution, a history of allergic diseases or a history of drug allergy;
  • Those who have had beverages or foods containing methylxanthine (coffee, tea, coke, chocolate and energy drinks), grapefruit (fruit juice) and alcohol within 48 hours (2 days) before the clinical study;
  • Those who have taken any drug that changes the activity of liver enzymes within 28 days before taking the product or during the study;
  • Those who have donated blood within 3 months before enrollment;
  • Those who have participated in any clinical studies within 3 months before enrollment;
  • Those who are the staff of the study site directly affiliated to this study or are their immediate family members. Immediate family members are defined as spouses, parents, children or siblings, whether related by blood or legally adopted;
  • Those who are employees of TenNor Therapeutics;
  • Other circumstances deemed by the investigator to be unsuitable for the subject to participate in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    TNP-2092 capsules

    In single ascending dose study, participants received single oral dose of TNP-2092 capsules 100 to 1200 mg in fasted state. In food effect study, participants received single oral dose of TNP-2092 capsules 400 mg in fasted or fed state in a two-sequence, two-period crossover design.

    Drug: TNP-2092 capsules

  • Placebo comparator
    Placebo

    In single ascending dose study, participants received single oral dose of TNP-2092 placebo capsules in fasted state. In food effect study, participants received single oral dose of TNP-2092 placebo capsules in fasted or fed state in a two-sequence, two-period crossover design.

    Drug: TNP-2092 placebo capsules

Interventions

  • Administered orally, 100 to 1200 mg

    Also known as: Rifaquizinone

  • DrugTNP-2092 placebo capsules

    Administered orally

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)

    To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 8 days after the first dosing.

  2. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

  3. Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

  4. Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

  5. Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

  6. Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

  7. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

  8. Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

  9. Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

  10. Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

  11. Terminal Elimination Half-life (T1/2) in Food Effect Study

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration

07

Results

Posted Apr 25, 2025

Participant flow

Participant flow — Overall Study
MilestoneTNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg - Group A (Fasting - Fed)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)Placebo (Fasting)TNP-2092 Capsules 400mg - Group B (Fed -Fasting)Placebo (Fed-fasting)Placebo (Fasting-fed)
Started888888811
Completed888888811
Not completed000000000

Outcome measures

PrimarySafety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)

To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to 8 days after the first dosing.
Reported as:
Count of participants · Participants
Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)
ParticipantsTNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg (Fasting )TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)Placebo (Fasting)TNP-2092 Capsules 400mg - (Fed)Placebo (Fed)
Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)01211120
PrimaryArea Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · h*µg/L
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study
h*µg/LTNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg Group A (Fasting)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Single Ascending Dose Study67.9 ± 29.9164 ± 65.7201 ± 71.4408 ± 480339 ± 176
PrimaryArea Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · h*µg/L
Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study
h*µg/LTNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg Group A (Fasting)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)
Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Single Ascending Dose Study65.4 ± 28.8161 ± 65.0197 ± 71.0404 ± 478335 ± 175
PrimaryMaximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · µg/L
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study
µg/LTNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg Group A (Fasting)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Single Ascending Dose Study16.7 ± 7.8041.7 ± 17.948.5 ± 20.897.4 ± 11770.3 ± 41.2
PrimaryTime to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · h
Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study
hTNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg Group A (Fasting)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)
Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Single Ascending Dose Study3.76 ± 0.463.50 ± 0.533.50 ± 1.203.75 ± 1.043.25 ± 1.17
PrimaryTerminal Elimination Half-life (T1/2) in Single Ascending Dose Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · h
Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study
hTNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg Group A (Fasting)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)
Terminal Elimination Half-life (T1/2) in Single Ascending Dose Study2.348 ± 1.04942.778 ± 1.19492.553 ± 1.26192.819 ± 0.84443.278 ± 1.1161
PrimaryArea Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · h*µg/L
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study
h*µg/LTNP-2092 Capsules 400mg (Fasting)TNP-2092 Capsules 400mg (Fed)
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) in Food Effect Study214 ± 91.7632 ± 349
PrimaryArea Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · h*µg/L
Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study
h*µg/LTNP-2092 Capsules 400mg (Fasting)TNP-2092 Capsules 400mg (Fed)
Area Under the Plasma Concentration Versus Time Curve From 0 to the Last Measurable Concentration (AUC0-last) in Food Effect Study211 ± 90.6628 ± 349
PrimaryMaximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · µg/L
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study
µg/LTNP-2092 Capsules 400mg (Fasting)TNP-2092 Capsules 400mg (Fed)
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 in Food Effect Study50.2 ± 25.2102 ± 36.6
PrimaryTime to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · h
Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study
hTNP-2092 Capsules 400mg (Fasting)TNP-2092 Capsules 400mg (Fed)
Time to Maximum Plasma Concentration (Tmax) of TNP-2092 in Food Effect Study3.56 ± 0.896.94 ± 2.72
PrimaryTerminal Elimination Half-life (T1/2) in Food Effect Study

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Before the first (Day1) administration (within 15 minutes), and 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h and 72 hours (h) after administration
Reported as:
Mean · h
Terminal Elimination Half-life (T1/2) in Food Effect Study
hTNP-2092 Capsules 400mg (Fasting)TNP-2092 Capsules 400mg (Fed)
Terminal Elimination Half-life (T1/2) in Food Effect Study2.74 ± 1.243.69 ± 0.98

Adverse events

Collected over Up to 8 days after the first dosing.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNP-2092 Capsules 100mg (Fasting)0/8 (0%)0/8 (0%)0/8 (0%)
TNP-2092 Capsules 200mg (Fasting)0/8 (0%)0/8 (0%)1/8 (12.5%)
TNP-2092 Capsules 400mg (Fasting )0/16 (0%)0/16 (0%)2/16 (12.5%)
TNP-2092 Capsules 800mg (Fasting)0/8 (0%)0/8 (0%)1/8 (12.5%)
TNP-2092 Capsules 1200mg (Fasting)0/8 (0%)0/8 (0%)1/8 (12.5%)
Placebo (Fasting)0/10 (0%)0/10 (0%)1/10 (10%)
TNP-2092 Capsules 400mg - (Fed)0/16 (0%)0/16 (0%)2/16 (12.5%)
Placebo (Fed)0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent other events
Most frequent other events
EventTNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg (Fasting )TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)Placebo (Fasting)TNP-2092 Capsules 400mg - (Fed)Placebo (Fed)
Activated partial thromboplastin time prolongedInvestigations0/80/80/160/81/80/100/160/2
Blood glucose increasedInvestigations0/80/80/161/80/80/100/160/2
DizzinessNervous system disorders0/81/80/160/80/80/100/160/2
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/80/80/160/80/81/100/160/2
Blood bilirubin increasedInvestigations0/80/80/160/80/80/101/160/2
Blood bilirubin unconjugated increasedInvestigations0/80/80/160/80/80/101/160/2
AcarodermatitisInfections and infestations0/80/80/160/80/80/101/160/2
Urinary tract infectionInfections and infestations0/80/81/160/80/80/100/160/2
PruritusSkin and subcutaneous tissue disorders0/80/80/160/80/80/101/160/2
AnaemiaBlood and lymphatic system disorders0/80/81/160/80/80/100/160/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg - Group A (Fasting-fed)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)Placebo (Fasting)TNP-2092 Capsules 400mg - Group B (Fed -Fasting)Placebo (Fed-fasting)Total
<=18 years000000000
Between 18 and 65 years8888898158
>=65 years000000000
Age, Continuous
Age, Continuous(years)TNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg - Group A (Fasting-fed)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)Placebo (Fasting)TNP-2092 Capsules 400mg - Group B (Fed -Fasting)Placebo (Fed-fasting)Total
Mean29.5 ± 9.0733.6 ± 7.9629.3 ± 5.3428.9 ± 10.3225.3 ± 5.8528.3 ± 8.7224.9 ± 5.9619 ± 029.1 ± 8.04
Sex: Female, Male
Sex: Female, Male(Participants)TNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg - Group A (Fasting-fed)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)Placebo (Fasting)TNP-2092 Capsules 400mg - Group B (Fed -Fasting)Placebo (Fed-fasting)Total
Female2344434024
Male6544464134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNP-2092 Capsules 100mg (Fasting)TNP-2092 Capsules 200mg (Fasting)TNP-2092 Capsules 400mg - Group A (Fasting-fed)TNP-2092 Capsules 800mg (Fasting)TNP-2092 Capsules 1200mg (Fasting)Placebo (Fasting)TNP-2092 Capsules 400mg - Group B (Fed -Fasting)Placebo (Fed-fasting)Total
American Indian or Alaska Native000000000
Asian8888898158
Native Hawaiian or Other Pacific Islander000000000
Black or African American000000000
White000000000
More than one race000000000
Unknown or Not Reported000000000
08

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Aug 2016, 1 month.

Results were first posted in Apr 2025, 8 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Dec 21, 2023
StartActual
Jun 6, 2016
Primary completionActual
Aug 2, 2016
CompletionActual
Aug 2, 2016
Results first posted
Apr 25, 2025
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06178718
Lead sponsor
TenNor Therapeutics (Suzhou) Limited
Responsible party
Sponsor
First posted
Dec 21, 2023
Start date
Jun 6, 2016
Primary completion
Aug 2, 2016
Completion
Aug 2, 2016
Results posted
Apr 25, 2025
Last update
Apr 25, 2025

Study contacts

Yanhua Ding, MD
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TNP-2092

Start the discussion